Dravet Syndrome

Also known as: Severe myoclonic epilepsy of infancy / Epilepsy, Myoclonic, Infantile, Severe

DrugDrug NameDrug Description
DB09118StiripentolStiripentol is an anticonvulsant drug used in the treatment of epilepsy as an adjunct therapy along with [DB00349] and [DB00313]. This drug is currently approved in the USA, Canada, and European countries as oral tablets marketed as Diacomit. FDA approval of this drug was granted on August 20, 2018 [L4352], [F1240]. Unrelated to other anticonvulsants, stiripentol belongs to the group of aromatic allylic alcohols and may potentiate the effect of other antiepileptic drugs (AEDs) due to pharmacokinetic interactions. It elevates the levels of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter that regulates electrical activity in the central nervous system.
DrugDrug NamePhaseStatusCount
DB09061Cannabidiol1 / 2Terminated1
DB09061Cannabidiol3Enrolling by Invitation1
DB00574Fenfluramine3Active Not Recruiting1
DB00574Fenfluramine3Enrolling by Invitation2
DB09118Stiripentol4No Longer Available1
DB00574FenfluramineNot AvailableAvailable1
DB09118StiripentolNot AvailableAvailable2
DB09118StiripentolNot AvailableNo Longer Available1